IgE Inhibitors
2 drugsAbout IgE
Immunoglobulin E (IgE) is an antibody that plays a central role in allergic reactions and parasitic infections. It triggers the release of inflammatory mediators upon binding to allergens, leading to hypersensitivity responses.
IgE is a well-validated drug target for respiratory diseases due to its role in allergic asthma. Currently, there is no genetic evidence directly linking IgE to specific diseases, but its function in allergy is well-established.
Two FDA-approved drugs, XOLAIR (omalizumab) and OMLYCLO, target IgE to alleviate allergy symptoms. These drugs are biologics, including one antibody, developed by Roche and CELLTRION INC.
Top IgE Drugs
The IgE drug market is concentrated with only two companies having approved drugs.
The limited number of players suggests high barriers to entry or an underserved market.
IgE Drug Modality Landscape
Modalities
Routes of Administration
IgE requires biologic approaches (biologic (other)), likely due to its structure or location.
Exploring alternative modalities like small molecules could provide a competitive advantage.
📈 Modality Evolution
Antibodies pioneered IgE targeting (2003), with other biologics entering more recently (2025).
IgE Clinical Trials 119 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IgE. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 27 | 24 | 2 | 1 | 92% |
| Phase 2 | 34 | 25 | 2 | 7 | 93% |
| Phase 3 | 27 | 24 | 1 | 2 | 96% |
| Phase 4 | 31 | 18 | 8 | 5 | 69% |
Top Sponsors
By Modality
IgE Drug Approval Timeline (2003 - 2025)
The first IgE-targeting drug was approved in 2003, with the most recent approval in 2025.
The 23-year span between approvals indicates a potentially slow-growing but persistent market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 61 (19 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IgE. A trial counts if an approved drug acting on IgE is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.